He Went to Prison for Gene-Editing Babies. Now He's Planning to Do It Again Chinese scientist He Jiankui wants to end Alzheimer's and thinks Silicon Valley is conducting a "Nazi eugenic experiment." In 2018, a nervous-looking He Jiankui took the stage at a scientific conference in Hong Kong. A hush settled over the packed auditorium as the soft-spoken Chinese scientist adjusted his microphone and confirmed the circulating media reports: He had created the world's first gene-edited babies . Three little girls were born with modifications to their genomes that were intended to protect them against HIV. The changes he'd made to their DNA were permanent and heritable, meaning they could be passed down to future generations.

Why personalized gene editing, genetic resurrections and embryo scoring made our list. Earlier this week, published its annual list of Ten Breakthrough Technologies. As always, it features technologies that made the news last year, and which--for better or worse--stand to make waves in the coming years. They're the technologies you should really be paying attention to. This year's list includes tech that's set to transform the energy industry, artificial intelligence, space travel --and of course biotech and health. Our breakthrough biotechnologies for 2026 involve editing a baby's genes and, separately, resurrecting genes from ancient species.

This year, hype around AI really exploded, and so did concerns about AI's environmental footprint. We also saw some surprising biotech developments. It's been a busy and productive year here at . We published magazine issues on power, creativity, innovation, bodies, relationships, and security . We hosted 14 exclusive virtual conversations with our editors and outside experts in our subscriber-only series, Roundtables, and held two events on MIT's campus. And we published hundreds of articles online, following new developments in computing, climate tech, robotics, and more.

Infertility is a major global health issue, and while in-vitro fertilization has improved treatment outcomes, embryo selection remains a critical bottleneck. Time-lapse imaging enables continuous, non-invasive monitoring of embryo development, yet most automated assessment methods rely solely on conventional morphokinetic features and overlook emerging biomarkers. Cytoplasmic Strings, thin filamentous structures connecting the inner cell mass and trophectoderm in expanded blastocysts, have been associated with faster blastocyst formation, higher blastocyst grades, and improved viability. However, CS assessment currently depends on manual visual inspection, which is labor-intensive, subjective, and severely affected by detection and subtle visual appearance. In this work, we present, to the best of our knowledge, the first computational framework for CS analysis in human IVF embryos. We first design a human-in-the-loop annotation pipeline to curate a biologically validated CS dataset from TLI videos, comprising 13,568 frames with highly sparse CS-positive instances. Building on this dataset, we propose a two-stage deep learning framework that (i) classifies CS presence at the frame level and (ii) localizes CS regions in positive cases. To address severe imbalance and feature uncertainty, we introduce the Novel Uncertainty-aware Contractive Embedding (NUCE) loss, which couples confidence-aware reweighting with an embedding contraction term to form compact, well-separated class clusters. NUCE consistently improves F1-score across five transformer backbones, while RF-DETR-based localization achieves state-of-the-art (SOTA) detection performance for thin, low-contrast CS structures. The source code will be made publicly available at: https://github.com/HamadYA/CS_Detection.

We'll keep following these developments, but this just wasn't their year. If you're a longtime reader, you probably know that our newsroom selects 10 breakthroughs every year that we think will define the future . This group exercise is mostly fun and always engrossing, but at times it can also be quite difficult. We collectively pitch dozens of ideas, and the editors meticulously review and debate the merits of each. We agonize over which ones might make the broadest impact, whether one is too similar to something we've featured in the past, and how confident we are that a recent advance will actually translate into long-term success. There is plenty of lively discussion along the way.

A startup's ads for controversial embryo tests hit the New York City subway. One day this fall, I watched an electronic sign outside the Broadway-Lafayette subway station in Manhattan switch seamlessly between an ad for makeup and one promoting the website Pickyourbaby.com, Inside the station, every surface was wrapped with more ads--babies on turnstiles, on staircases, on banners overhead. To his mind, one should be as accessible as the other. Nucleus is a young, attention-seeking genetic software company that says it can analyze genetic tests on IVF embryos to score them for 2,000 traits and disease risks, letting parents pick some and reject others. This is possible because of how our DNA shapes us, sometimes powerfully.

Advanced in organs on chips, digital twins, and AI are ushering in a new era of research and drug development. Earlier this week, the UK's science minister announced an ambitious plan: to phase out animal testing. Testing potential skin irritants on animals will be stopped by the end of next year, according to a strategy released on Tuesday . By 2027, researchers are "expected to end" tests of the strength of Botox on mice. And drug tests in dogs and nonhuman primates will be reduced by 2030. The news follows similar moves by other countries.

Entrepreneurs say it's time to safety-test designer baby technology. A West Coast biotech entrepreneur says he's secured $30 million to form a public-benefit company to study how to safely create genetically edited babies, marking the largest known investment into the taboo technology. The new company, called Preventive, is being formed to research so-called "heritable genome editing," in which the DNA of embryos would be modified by correcting harmful mutations or installing beneficial genes. The goal would be to prevent disease. Preventive was founded by the gene-editing scientist Lucas Harrington, who described his plans yesterday in a blog post announcing the venture. Preventive, he said, will not rush to try out the technique but instead will dedicate itself "to rigorously researching whether heritable genome editing can be done safely and responsibly."

Scientists are using AI to better predict embryo health in real time. Embryologists are the scientists behind the scenes of in vitro fertilization who oversee the development and selection of embryos, prepare them for transfer, and maintain the lab environment. They've been a critical part of IVF for decades, but their job has gotten a whole lot busier in recent years as demand for the fertility treatment skyrockets and clinics struggle to keep up. The United States is in fact facing a critical shortage of both embryologists and genetic counselors. Klaus Wiemer, a veteran embryologist and IVF lab director, believes artificial intelligence might help by predicting embryo health in real time and unlocking new avenues for productivity in the lab. Wiemer is the chief scientific officer and head of clinical affairs at Fairtility, a company that uses artificial intelligence to shed light on the viability of eggs and embryos before proceeding with IVF.

A new field of science claims to be able to predict aesthetic traits, intelligence, and even moral character in embryos. Is this the next step in human evolution or something more dangerous? Consider, if you will, the translucent blob in the eye of a microscope: a human blastocyst, the biological specimen that emerges just five days or so after a fateful encounter between egg and sperm. This bundle of cells, about the size of a grain of sand pulled from a powdery white Caribbean beach, contains the coiled potential of a future life: 46 chromosomes, thousands of genes, and roughly six billion base pairs of DNA--an instruction manual to assemble a one-of-a-kind human. Now imagine a laser pulse snipping a hole in the blastocyst's outermost shell so a handful of cells can be suctioned up by a microscopic pipette. This is the moment, thanks to advances in genetic sequencing technology, when it becomes possible to read virtually that entire instruction manual. An emerging field of science seeks to use the analysis pulled from that procedure to predict what kind of a person that embryo might become. Some parents turn to these tests to avoid passing on devastating genetic disorders that run in their families. A much smaller group, driven by dreams of Ivy League diplomas or attractive, well-behaved offspring, are willing to pay tens of thousands of dollars to optimize for intelligence, appearance, and personality. Some of the most eager early boosters of this technology are members of the Silicon Valley elite, including tech billionaires like Elon Musk, Peter Thiel, and Coinbase CEO Brian Armstrong. Embryo selection is less like a build-a-baby workshop and more akin to a store where parents can shop for their future children from several available models--complete with stat cards. But customers of the companies emerging to provide it to the public may not be getting what they're paying for. Genetics experts have been highlighting the potential deficiencies of this testing for years.